Eisai’s Dayvigo Granted NMPA Approval for Insomnia Treatment
Japan-based Eisai Co., Ltd. (TYO: 4523) announced that it has received marketing approval from China’s...
Product approvals
Fosun Pharma’s HLX22 Granted Orphan Drug Designation by EU Commission
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...
Bio-Thera Solutions’ BAT2206 Biosimilar of Stelara Gains FDA Approval
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) announced that it has received Biologic License Application (BLA)...
Jemincare’s Irinotecan Liposome Injection Gains NMPA Approval for Pancreatic Cancer
China-based Jiangxi Jemincare Group announced that it has received marketing approval from the National Medical...
GSK’s Blenrep Recommended for EU Approval in Multiple Myeloma
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that its Blenrep (belantamab mafodotin) has been...
Grand Pharma’s GPN01768 Approved in Macau for Demodectic Blepharitis
Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its New Drug Application (NDA) for...
Medtronic’s Prevail DCB Gains CE Mark for Expanded Coronary Disease Indications
US-Irish firm Medtronic (NYSE: MDT) announced that its Prevail paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA)...
Zhongsheng Pharma’s Anruiwei Receives NMPA Approval for Influenza A
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received marketing approval...
GSK’s Nucala Receives FDA Approval for COPD Treatment
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that it has received marketing approval from...
NMPA Approves Bayer/Regeneron’s Eylea HD for Wet AMD Treatment
China’s National Medical Products Administration (NMPA) has approved Bayer (ETR: BAYN) and Regeneron’s (NASDAQ: REGN)...
Jacobio Pharma’s Glecirasib Approved by NMPA for KRAS G12C+ NSCLC
China-based Jacobio Pharma (HKG: 1167) announced that it has received marketing approval from the National...
Hengrui Pharmaceuticals’ Retagliptin and Metformin Approved by NMPA for Type 2 Diabetes
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received marketing...
Roche’s Susvimo Gets FDA Approval for Diabetic Retinopathy
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Susvimo (ranibizumab) 100mg/mL intravitreal ocular...
InnoCare Pharma’s Minjuvi Gains NMPA Approval for DLBCL Treatment
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the National Medical Products Administration (NMPA)...
Uni-Bio Science’s Generic Diquas Accepted for NMPA Review
China’s Uni-Bio Science Group (HKG: 0690) announced that a market filing for its generic version...
Eli Lilly’s Kisunla Approved in Australia for Alzheimer’s Treatment
The Australian Therapeutic Goods Administration (TGA) this week approved Eli Lilly and Company’s (NYSE: LLY)...
Boehringer Ingelheim’s Metalyse Approved in China for Acute Ischemic Stroke
Germany-based pharmaceutical leader Boehringer Ingelheim announced receiving marketing approval from China’s National Medical Products Administration...
GSK’s Blenrep Receives Marketing Approval in Japan for Multiple Myeloma
UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) announced that it has received marketing approval from...
Hainan Shuangcheng’s Generic Eptifibatide Gains TGA Marketing Approval in Australia
China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has received marketing approval from Australia’s Therapeutic...
Stryker’s OptaBlate BVN System Gains FDA 510(k) Clearance
US-based Stryker (NYSE: SYK) announced this week that its OptaBlate Basivertebral Nerve Ablation (BVN) system...